Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¸°­ÆíÆò»óÇǼ¼Æ÷¾Ï ¼¼Æ÷ÁÖ¿Í °ñÀ°Á¾ ¼¼Æ÷ÁÖ¿¡¼­ TaxolR°ú CisplatinÀÇ Ç×¾Ï È¿°ú¿¡ ´ëÇÑ ¿¬±¸

ANTI-TUMOR EFFECT OF TAXOLR AND CISPLATIN IN ORAL SQUAMOUS CELL CARCINOMA AND OSTEOSARCOMA CELL LINES

´ëÇѱ¸°­¾Ç¾È¸é¿Ü°úÇÐȸÁö 1999³â 25±Ç 3È£ p.236 ~ 241
³ëÀº¼®, ±è¸íÁø,
¼Ò¼Ó »ó¼¼Á¤º¸
³ëÀº¼® (  ) - °æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ¾È°úÇб³½Ç
±è¸íÁø (  ) - ¼­¿ï´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç

Abstract

°á·Ð
»ç¶÷ÀÇ ±¸°­ÆíÆò»óÇÇ¾Ï ¼¼Æ÷ÁÖ (KB)¿Í °ñÀ°Á¾¼¼Æ÷ÁÖ (HOS)ÀÇ taxol ¹× cisplatin¿¡ ´ëÇÑ
Ç׾ϰ¨¼ö¼º ÃøÁ¤À» MIT¹ýÀ» ÀÌ¿ëÇÏ¿© ½ÃÇàÇÏ¿© ´ÙÀ½°ú °°Àº °á·Ð¸¦ ¾ò¾ú´Ù.
1 Taxol°ú cisplatinÀº °¢ ¼¼Æ÷ÁÖ¿¡ ´ëÇÏ¿© À¯ÀÇÇÏ°Ô ³óµµÀÇÁ¸¼ºÀÇ Ç×¾Ï È¿°ú¸¦ ³ªÅ¸³Â°í,
24½Ã°£±º°ú 72½Ã°£ ¹è¾ç±º¿¡¼­ taxol°ú cisplatinÀº °¢°¢ À¯ÀÇÇÏ°Ô ½Ã°£ÀÇÁ¸¼ºÀÇ Ç×¾ÏÈ¿°ú¸¦
º¸¿´´Ù.
2. IC50¿¡¼­ÀÇ assay AUC¿Í ÀÓ»óÀûÀ¸·Î µµ´Þ °¡´ÉÇÑ AUC¿ÍÀÇ ºñ±³¿¡¼­
cisplatin-KB±º¿¡¼­ assay AUC°¡ ÀûÀº °ÍÀ¸·Î ³ªÅ¸³ª ÀÓ»óÀû Àû¿ëÀÇ À¯ÀǼºÀ» È®ÀÎÇÒ ¼ö
ÀÖ¾ú´Ù. ¹Ý¸é ³ª¸ÓÁö ±º¿¡¼­´Â assay AUC°¡ Å« °ÍÀ¸·Î ³ªÅ¸³ª ÀÓ»óÀû ´Üµ¶Àû¿ëÀÇ À¯¿ë¼º
ÀÌ ¶³¾îÁö´Â °ÍÀ¸·Î ÃßÁ¤µÈ´Ù. TaxolÀº ÀÓ»óÀû µµ´Þ °¡´ÉÇÑ AUC¿¡¼­ Ãß·ÐµÈ ³óµµ ³»¿¡¼­
KB¼¼Æ÷ÁÖ¿¡ ´ëÇؼ­ cisplatinº¸´Ù À¯ÀǼº ÀÖ°Ô °­ÇÑ Ç×¾ÏÈ¿°ú¸¦ ³ªÅ¸³Â´Ù.
ÀÌ»óÀÇ ½ÇÇè°á°ú¸¦ Á¾ÇÕÇÏ¿© º¼ ¶§ taxolÀÇ ±¸°­ÆíÆò»óÇǼ¼Æ÷¾Ï¿¡ ´ëÇÑ ÀÓ»óÀû Àû¿ëÀÌ À¯
È¿ÇÒ °ÍÀ¸·Î ±â´ëµÇ¸ç ÀÌ¿¡ ´ëÇÑ in vivo study, Ÿ ¾àÁ¦¿ÍÀÇ º´ÇÕÈ¿°ú, ¾àÁ¦³ëÃâÇÕÀÇ Áõ´ë
¹æ¹ýµî¿¡ ´ëÇÏ¿© Â÷ÈÄ Áö¼ÓÀûÀÎ ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ç·áµÇ¾ú´Ù.

Object
Docetaxel (TaxolR), which has been used for breast cancer and ovarian
cancer and cisplatin were applied to KB and HOS cell lines. Relative cytotoxicity of
each drug to cell lines and its efficiency was evaluated and analyzed for clinical
application.
Method and Material
Groups were defined by drugs and cell lines combination and were evaluated. We
cultured cell line under routine environment and determined optimal cell number and
drug concentration. Drugs were applied to cell lines and we measured the optical density
with ELISA after MTT application. Statistical analysis was made and clinical availability
was evaluated. IC50 and assay AUC could be calculated. Clinical
availability was evaluated and comparisons of anti-tumor effect of each drug on cell
lines were performed.
Results
1. Anti-tumor effects of taxol and cisplatin on each cell lines showed time and dose
dependent relations with significance statistically.
2. Assay AUC in IC50 was higher than clinically achievable AUC in all
groups except cisplatin-KB group. Anti-tumor effect of taxol to KB cell line was higher
than that of cisplatin in concentration calculated from the clinically achievable AUC.
So, we could suggest that taxol could be also used as a antitumor durg for oral
cancer. Further study that is, in vivo study, evaluation of combination therapy with
other drug, and method of increasing of AUC would be necessary.

Å°¿öµå

Taxol; Chemosensitivity; Oral squamous cell carcinoma;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed